Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

SAN MATEO, Calif., April 28, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent entitled, "Methods and Compositions for Administration of TRPV1 Agonists."  The allowed claims include method of use, formulation and system claims.  The patent scheduled to issue from this application is expected to expire in 2024, with additional patent term expected in excess of approximately two years due to Patent Term Adjustment.

Anthony DiTonno, President and CEO, commented, "We believe that the Notice of Allowance for our second generation product is very significant and welcome news.  The target product profile for NGX-1998 includes similar efficacy, but a greatly reduced treatment time for NGX-1998 when compared to Qutenza®.  We believe that NGX-1998 has the potential to be a successful product in neuropathic pain, if approved for marketing, and that the granting of this patent will provide us with long-term protection for this product candidate."  

Similar claims have been issued to NeurogesX in a Eurasian patent.  The Company also received a Notice of Allowance in a related Canadian patent application.

Other Recent Patent Issuances

NeurogesX continues to be focused on developing the underlying intellectual property that supports its current and potential future product families, both in the United States and major markets throughout the world.  Since 2009, the Company has been granted patents covering capsaicin-related products such as capsaicin prodrugs, capsaicin oils, a skin cleansing gel and a specific type of capsaicin patch.  Recent patent issuances include the following:  

    '/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
(Date:7/10/2014)... of Huddersfield could help to improve the quality of ... such as butter, mayonnaise, yoghurt and fruit drinks ... for her work. , Katerina gained her MSc degree ... now she has embarked on research for a PhD. ... is investigating the potential of carbohydrates extracted from the ...
(Date:7/10/2014)... men with localized prostate cancer were more likely ... received less effective treatments and survived for shorter ... depressed, a UCLA study has found. , The ... factors such as bias against the mentally ill, ... man,s lack of investment in his general health ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2
... Results presented today from the Atrial Fibrillation Ablation ... undergoing a catheter ablation for atrial fibrillation have ... precipitating factors are rare. The survey, which is ... programme, also confirmed that symptoms are present in ...
... team of surgeons at UT Southwestern Medical Center expects ... within a year, making the institution just the sixth ... intricate surgery. UT Southwestern received Institutional Review Board ... Transplant specialists are now screening potential patients who would ...
... MONDAY, Aug. 29 (HealthDay News) -- Hurricanes. Earthquakes. Floods. Tornadoes. ... events have left adults reeling as one disaster seems to ... relent and no apparent end in sight. Imagine, then, ... they see this stuff is everywhere," said Robin Goodman, a ...
... -- The width of a CEO,s face may predict how ... Researchers compared the photos of 55 male CEOs of Fortune ... only men because previous research found that a link between ... firms of CEOs with wider faces, relative to face height, ...
... -- Effective memory is a key ability for independent living ... is among the first to report that social partners can ... that helps middle-aged couples with memory tasks doesn,t seem to ... Margrett, an assistant professor in human development and family studies, ...
... , MONDAY, Aug. 29 (HealthDay News) -- Many ... discharged from U.S. hospitals return to the emergency department ... an outpatient clinic, a new study finds. These ... refills of pain medications. The researchers examined the ...
Cached Medicine News:Health News:The first European registry to evaluate the real-life epidemiology of atrial fibrillation ablation 2Health News:The first European registry to evaluate the real-life epidemiology of atrial fibrillation ablation 3Health News:UT Southwestern launches hand transplant program 2Health News:For Kids, Natural Disasters Can Whip Up Worries 2Health News:For Kids, Natural Disasters Can Whip Up Worries 3Health News:Study examines how couples' collaborative dialogue may assist in a spouse's memory 2Health News:Study examines how couples' collaborative dialogue may assist in a spouse's memory 3Health News:Many Use ER for Routine Follow-Up Care After Hospital Discharge 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... This user-friendly instrument ... Plasma Protein analyzer for ... It is a well ... reliable results for a ...
For Detection of Bile Component in Reflux Disease...
Medicine Products: